Patient, physician, and policy factors underlying variation in use of telemedicine for radiation oncology cancer care.
Autor: | De B; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fu S; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chen YS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Das P; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ku K; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Maroongroge S; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Woodhouse KD; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hoffman KE; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Nguyen QN; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Reed VK; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chen AB; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Koong AC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Smith BD; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Smith GL; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Cancer medicine [Cancer Med] 2022 May; Vol. 11 (10), pp. 2096-2105. Date of Electronic Publication: 2022 Mar 16. |
DOI: | 10.1002/cam4.4555 |
Abstrakt: | Background: Oncology telemedicine was implemented rapidly after COVID-19. We examined multilevel correlates and outcomes of telemedicine use for patients undergoing radiotherapy (RT) for cancer. Methods: Upon implementation of a telemedicine platform at a comprehensive cancer center, we analyzed 468 consecutive patient RT courses from March 16, 2020 to June 1, 2020. Patients were categorized as using telemedicine during ≥1 weekly oncologist visits versus in-person oncologist management only. Temporal trends were evaluated with Cochran-Armitage tests; chi-squared test and multilevel multivariable logistic models identified correlates of use and outcomes. Results: Overall, 33% used telemedicine versus 67% in-person only oncologist management. Temporal trends (p Conclusion: Though toxicities were similar with telemedicine oncology management, there remained lower uptake among non-White patients. Continuing strategies for oncology telemedicine implementation should address multilevel patient, physician, and policy factors to optimize telemedicine's potential to surmount-and not exacerbate-barriers to quality cancer care. (© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.) |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |